Pretreatment with Growth Hormone-Releasing Peptide-2 Directly Protects against the Diastolic Dysfunction of Myocardial Stunning in an Isolated, Blood-Perfused Rabbit Heart Model** Presented in part at the Annual Meeting of the Belgian Endocrine Society, Brussels, November 20, 1999 (Young Investigato
暂无分享,去创建一个
[1] T. Hedner,et al. The Growth Hormone Secretagogue Hexarelin Improves Cardiac Function in Rats after Experimental Myocardial Infarction1. , 2000, Endocrinology.
[2] M. Nishihara,et al. Fas/Fas ligand system in prolactin-induced apoptosis in rat corpus luteum: possible role of luteal immune cells. , 1999, Biochemical and biophysical research communications.
[3] M. Ashraf,et al. Role of protein kinase C in mitochondrial KATP channel-mediated protection against Ca2+ overload injury in rat myocardium. , 1999, Circulation research.
[4] R. Musters,et al. PKC-dependent preconditioning with norepinephrine protects sarcoplasmic reticulum function in rat trabeculae following metabolic inhibition. , 1999, Journal of molecular and cellular cardiology.
[5] E. Arvat,et al. Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans , 1999, Journal of endocrinological investigation.
[6] E. Marbán,et al. Molecular and cellular mechanisms of myocardial stunning. , 1999, Physiological reviews.
[7] P. Pagliaro,et al. The effects of ischemic preconditioning on resting coronary flow and reactive hyperemia: involvement of A1 adenosine receptors. , 1999, Life sciences.
[8] E. Lascano,et al. Left ventricular regional systolic and diastolic function in conscious sheep undergoing ischemic preconditioning. , 1999, Cardiovascular research.
[9] G. Heusch,et al. AT1 receptor blockade in experimental myocardial ischemia/reperfusion , 2003, Basic Research in Cardiology.
[10] M. Lomsky,et al. A placebo-controlled study of growth hormone in patients with congestive heart failure. , 1998, European heart journal.
[11] D. Griese,et al. Differential effects of growth hormone on cardiomyocyte and extracellular matrix protein remodeling following experimental myocardial infarction. , 1998, Cardiovascular research.
[12] M. Bernareggi,et al. Protectant activity of hexarelin or growth hormone against postischemic ventricular dysfunction in hearts from aged rats. , 1998, Journal of cardiovascular pharmacology.
[13] P. Poole‐Wilson,et al. Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy , 1998, The Lancet.
[14] T. Hedner,et al. Growth hormone improves cardiac function in rats with experimental myocardial infarction , 1997, European journal of clinical investigation.
[15] P. Douglas,et al. Growth hormone attenuates early left ventricular remodeling and improves cardiac function in rats with large myocardial infarction. , 1997, Journal of the American College of Cardiology.
[16] Patrick R. Griffin,et al. A Receptor in Pituitary and Hypothalamus That Functions in Growth Hormone Release , 1996, Science.
[17] B. Biondi,et al. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. , 1996, The New England journal of medicine.
[18] P. Douglas,et al. Differential cardiac effects of growth hormone and insulin-like growth factor-1 in the rat. A combined in vivo and in vitro evaluation. , 1996, Circulation.
[19] C. Bowers,et al. The effects of GH-releasing peptide-6 (GHRP-6) and GHRP-2 on intracellular adenosine 3',5'-monophosphate (cAMP) levels and GH secretion in ovine and rat somatotrophs. , 1996, The Journal of endocrinology.
[20] R. Clark,et al. Beneficial Effects of Growth Hormone and Insulin‐Like Growth Factor‐1 in Experimental Heart Failure in Rats Treated with Chronic ACE Inhibition , 1995, Journal of cardiovascular pharmacology.
[21] R. Clark,et al. Growth hormone improves cardiac performance in experimental heart failure. , 1995, Circulation.
[22] R. Mentzer,et al. Salutary effects of exogenous adenosine administration on in vivo myocardial stunning. , 1995, The Journal of thoracic and cardiovascular surgery.
[23] J. Ross,et al. Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure. , 1995, The Journal of clinical investigation.
[24] R. Kloner,et al. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. , 1994, The Journal of clinical investigation.
[25] P. Marzullo,et al. Growth hormone and the heart , 2001, Endocrine Updates.
[26] B. Hille,et al. Growth hormone-releasing hexapeptide elevates intracellular calcium in rat somatotropes by two mechanisms. , 1994, Endocrinology.
[27] K. Caidahl,et al. Cardiovascular and renal effects of growth hormone * , 1994, Clinical endocrinology.
[28] C. Carella,et al. Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. , 1993, The Journal of clinical endocrinology and metabolism.
[29] L. Saccá,et al. Cardiac structural and functional abnormalities in adult patients with growth hormone deficiency. , 1993, The Journal of clinical endocrinology and metabolism.
[30] M. Borgers,et al. R56865, a Na(+)- and Ca(2+)-overload inhibitor, reduces myocardial ischemia-reperfusion injury in blood-perfused rabbit hearts. , 1993, Journal of molecular and cellular cardiology.
[31] L. Becker,et al. Relation between glycolysis and calcium homeostasis in postischemic myocardium. , 1992, Circulation research.
[32] Y. Lecarpentier,et al. Effects of chronic growth hormone hypersecretion on intrinsic contractility, energetics, isomyosin pattern, and myosin adenosine triphosphatase activity of rat left ventricle. , 1990, The Journal of clinical investigation.
[33] H. Orskov,et al. Increased myocardial contractility following growth hormone administration in normal man. An echocardiographic study. , 1988, Danish medical bulletin.
[34] J. Jansson,et al. Growth hormone-releasing hormone. , 1986, Endocrine reviews.
[35] F. Momany,et al. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. , 1984, Endocrinology.
[36] P. D. de Moor,et al. Heterogeneity of human growth hormone in serum. , 1974, Annales d'endocrinologie.
[37] M. Beznák. The restoration of cardiac hypertrophy and blood pressure in hypophysectomized rats by large doses of lyophilized anterior pituitary and growth hormone , 1954, Journal of Physiology.